163 related articles for article (PubMed ID: 33099927)
1. Role of MAPK activity in PD-L1 expression in hepatocellular carcinoma cells.
Xing S; Chen S; Yang X; Huang W
J BUON; 2020; 25(4):1875-1882. PubMed ID: 33099927
[TBL] [Abstract][Full Text] [Related]
2. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.
Stutvoet TS; Kol A; de Vries EG; de Bruyn M; Fehrmann RS; Terwisscha van Scheltinga AG; de Jong S
J Pathol; 2019 Sep; 249(1):52-64. PubMed ID: 30972766
[TBL] [Abstract][Full Text] [Related]
3. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.
Liu Z; Ning F; Cai Y; Sheng H; Zheng R; Yin X; Lu Z; Su L; Chen X; Zeng C; Wang H; Liu L
Cancer Commun (Lond); 2021 Jan; 41(1):62-78. PubMed ID: 34236149
[TBL] [Abstract][Full Text] [Related]
4. MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells.
Zou J; Zhuang M; Yu X; Li N; Mao R; Wang Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Mol Immunol; 2018 Sep; 101():203-209. PubMed ID: 30007230
[TBL] [Abstract][Full Text] [Related]
5. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
6. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Yan Y; Zheng L; Du Q; Yan B; Geller DA
Cancer Immunol Immunother; 2020 Sep; 69(9):1891-1903. PubMed ID: 32377817
[TBL] [Abstract][Full Text] [Related]
7. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
8. M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling.
Zong Z; Zou J; Mao R; Ma C; Li N; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Front Immunol; 2019; 10():1643. PubMed ID: 31379842
[TBL] [Abstract][Full Text] [Related]
9. Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-γ Signaling.
Li Z; Gao WQ; Wang P; Wang TQ; Xu WC; Zhu XY; Liu H
Curr Cancer Drug Targets; 2020; 20(11):868-874. PubMed ID: 32748749
[TBL] [Abstract][Full Text] [Related]
10. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
[TBL] [Abstract][Full Text] [Related]
11. Prostasin regulates PD-L1 expression in human lung cancer cells.
Chen LM; Chai JC; Liu B; Strutt TM; McKinstry KK; Chai KX
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34240739
[TBL] [Abstract][Full Text] [Related]
12. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
[TBL] [Abstract][Full Text] [Related]
13. Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β.
Hirayama A; Tanaka K; Tsutsumi H; Nakanishi T; Yamashita S; Mizusaki S; Ishii Y; Ota K; Yoneshima Y; Iwama E; Okamoto I
Front Immunol; 2023; 14():1192861. PubMed ID: 37441079
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA
Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356
[TBL] [Abstract][Full Text] [Related]
15. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
[TBL] [Abstract][Full Text] [Related]
16.
He L; Xu K; Niu L; Lin L
Pharm Biol; 2022 Dec; 60(1):1710-1720. PubMed ID: 36086826
[TBL] [Abstract][Full Text] [Related]
17. c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway.
Xu R; Liu X; Li A; Song L; Liang J; Gao J; Tang X
J Mol Med (Berl); 2022 Apr; 100(4):585-598. PubMed ID: 35122106
[TBL] [Abstract][Full Text] [Related]
18. PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells.
Wei H; Mao Y; Zhang H; Wu F; Zhang Y
Immunol Invest; 2023 Apr; 52(3):343-363. PubMed ID: 36762677
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway.
Qin X; Liu C; Zhou Y; Wang G
Cell Mol Biol (Noisy-le-grand); 2010 Sep; 56 Suppl():OL1366-72. PubMed ID: 20937224
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment.
Mimura K; Kua LF; Shiraishi K; Kee Siang L; Shabbir A; Komachi M; Suzuki Y; Nakano T; Yong WP; So J; Kono K
Cancer Sci; 2014 Oct; 105(10):1236-44. PubMed ID: 25154680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
